Literature DB >> 7381647

Doxorubicin cardiotoxicity in children.

T Biancaniello, R A Meyer, K Y Wong, C Sager, S Kaplan.   

Abstract

To characterize the long-term effects of doxorubicin hydrochloride (Adriamycin) on left ventricular function, a total of 588 echocardiograms were obtained prospectively in 46 children who were treated for malignancy. We found shortening fraction of the left ventricle to be more useful than systolic time intervals for detecting cardiotoxic effects. Abnormal cardiac function occurred in 43% of patients but only 4% developed congestive heart failure which was irreversible. There appeared to be strong individual variation in response to the effects of doxorubicin on the heart unrelated to treatment regimen, age of onset of treatment, or total cumulative dose. If the SF remained normal it was possible to give a dose greater than 550 mg/m2. If cardiac dysfunction occurred following cessation of doxorubicin, it did so within five months in 95% of patients. Discontinuing doxorubicin therapy in patients with SF LEss than 20% who did not have clinical signs of congestive heart failure resulted in improved shortening fraction and administration of digoxin did not further improve the SF. Sequential echographic evaluation of cardiac function at frequent intervals has proven to be useful during and following treatment with doxorubicin.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7381647     DOI: 10.1016/s0022-3476(80)80128-4

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  9 in total

1.  Computer assisted echocardiographic assessment of left ventricular function before and after anatomical correction of transposition of the great arteries.

Authors:  F W Arensman; R Radley-Smith; L Grieve; D G Gibson; M H Yacoub
Journal:  Br Heart J       Date:  1986-02

Review 2.  Sex-Specific Cardiovascular Risks of Cancer and Its Therapies.

Authors:  Nicholas S Wilcox; Seth J Rotz; McKay Mullen; Evelyn J Song; Betty Ky Hamilton; Javid Moslehi; Saro H Armenian; Joseph C Wu; June-Wha Rhee; Bonnie Ky
Journal:  Circ Res       Date:  2022-02-17       Impact factor: 17.367

3.  Anthracycline cardiomyopathy.

Authors:  N L Kobrinsky; N K Ramsay; W Krivit
Journal:  Pediatr Cardiol       Date:  1982       Impact factor: 1.655

4.  Histamine 2 receptor antagonism elicits protection against doxorubicin-induced cardiotoxicity in rodent model.

Authors:  Sundar Kumar Kondru; Ajay Godwin Potnuri; Lingesh Allakonda; Prasad Konduri
Journal:  Mol Cell Biochem       Date:  2017-09-08       Impact factor: 3.396

Review 5.  Doxorubicin (adriamycin) cardiomyopathy.

Authors:  E Saltiel; W McGuire
Journal:  West J Med       Date:  1983-09

6.  Scintigraphic evaluation of myocardial uptake of thallium 201 and technetium 99m pyrophosphate utilizing a rat model of chronic doxorubicin cardiotoxicity.

Authors:  M Miyagawa; S Tanada; K Hamamoto
Journal:  Eur J Nucl Med       Date:  1991

Review 7.  Hematologic and oncologic complications in the critically ill child.

Authors:  S McIntosh
Journal:  Yale J Biol Med       Date:  1984 Mar-Apr

Review 8.  Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs.

Authors:  Marilisa Molinaro; Pietro Ameri; Giancarlo Marone; Mario Petretta; Pasquale Abete; Fabio Di Lisa; Sabino De Placido; Domenico Bonaduce; Carlo G Tocchetti
Journal:  Biomed Res Int       Date:  2015-10-25       Impact factor: 3.411

9.  Lipid Emulsion Inhibits the Late Apoptosis/Cardiotoxicity Induced by Doxorubicin in Rat Cardiomyoblasts.

Authors:  Raghavendra Baregundi Subbarao; Seong-Ho Ok; Soo Hee Lee; Dawon Kang; Eun-Jin Kim; Ji-Yoon Kim; Ju-Tae Sohn
Journal:  Cells       Date:  2018-09-20       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.